Edition:
India

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

20.00USD
20 Apr 2018
Change (% chg)

$-0.20 (-0.99%)
Prev Close
$20.20
Open
$20.10
Day's High
$20.60
Day's Low
$19.75
Volume
54,664
Avg. Vol
221,532
52-wk High
$25.70
52-wk Low
$12.50

Chart for

About

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $1,620.01
Shares Outstanding(Mil.): 74.31
Dividend: --
Yield (%): --

Financials

  IPXL.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -8.08 -- --
ROI: -39.49 14.84 14.38
ROE: -72.27 16.34 16.07

BRIEF-Impax Launches Generic Version Of Estrace Cream

* IMPAX LAUNCHES A GENERIC VERSION OF ESTRACE® CREAM (ESTRADIOL VAGINAL CREAM, USP, 0.01%)

06 Apr 2018

Impax reaches $20 million deal to end trial over generic drug's delay

BOSTON Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn.

29 Mar 2018

UPDATE 2-Impax reaches $20 mln deal to end trial over generic drug's delay

BOSTON, March 29 Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn.

29 Mar 2018

Impax reaches $20 mln deal to end trial over generic drug's delay

BOSTON, March 29 Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn.

29 Mar 2018

BRIEF-Impax Shareholders Approve Proposed Business Combination With Amneal

* IMPAX SHAREHOLDERS APPROVE PROPOSED BUSINESS COMBINATION WITH AMNEAL

28 Mar 2018

Impax settles retailers' antitrust cases over generic drug's delay

BOSTON, March 26 Impax Laboratories Inc has reached a mid-trial settlement with retailers including CVS Health Corp and Rite Aid Corp who accused the drugmaker of entering into an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn.

26 Mar 2018

Impax broke U.S. antitrust law by delaying generic drug, jury told

BOSTON Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer.

13 Mar 2018

UPDATE 1-Impax broke U.S. antitrust law by delaying generic drug, jury told

BOSTON, March 12 Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer.

13 Mar 2018

Impax faces U.S. antitrust trial over generic acne drug's delay

BOSTON, March 12 Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer.

12 Mar 2018

Impax to pay $35 mln to settle part of Solodyn antitrust litigation

BOSTON, March 10 Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn.

10 Mar 2018

Earnings vs. Estimates